Skip to main content
TipRanks
Go Ultimate75% OFF

United Therapeutics (UTHR) AI Stock Analysis

787 Followers
UTHR

United Therapeutics

(NASDAQ:UTHR)

Select Model
Rating:85Outperform
Price Target:$707.00â–²(20.26% Upside)
Action:reiterated
Date:11/04/26

UTHR scores highly primarily due to outstanding financial strength (premium margins, strong cash generation, and effectively no debt) and a strong technical setup with price above all major moving averages. The score is moderated by slowing top-line growth and weaker recent free-cash-flow trend, plus regulatory/execution timing risks highlighted on the earnings call (notably the delayed soft mist inhaler filing and ralinepag supply-chain compliance issue).

Positive Factors
High profitability and cash generationUnited Therapeutics combines exceptional margins with substantial operating cash generation, indicating strong economics in its established PAH portfolio. This profitability supports continued investment in commercial capabilities, clinical programs, and new delivery technologies while preserving resilience through business-cycle changes.
Negative Factors
Revenue growth has materially slowedThe sharp deceleration from historical expansion to roughly flat trailing revenue indicates that the established portfolio is entering a more mature phase. Sustaining earnings growth will therefore depend increasingly on successful launches, broader indications, and converting pipeline programs into commercial products.

United Therapeutics Key Performance Indicators (KPIs)

Revenue by GeographyShows where United Therapeutics earns its sales and highlights dependence on key markets—typically the U.S. versus international regions—so you can judge how sensitive revenue is to U.S. reimbursement decisions, regional regulatory shifts, and currency moves. A heavy U.S. skew signals vulnerability to domestic pricing and payer actions, while growing ex‑U.S. sales point to new patient pools and diversification of risk.

$0.00$200.00M$400.00M$600.00M$800.00MMar 21Jun 21Sep 21Dec 21Mar 22Jun 22Sep 22Dec 22Mar 23Jun 23Sep 23Dec 23Mar 24Jun 24Sep 24Dec 24Mar 25Jun 25Sep 25Dec 25Mar 26Jun 26Sep 26
Chart Insights

International revenue has been lumpy but just staged a meaningful rebound to near‑record levels, indicating the doubled sales force and record starts/referrals are beginning to translate abroad. That suggests commercial investments can drive outsized upside, but revenue often lags patient metrics and nebulized Tyvaso faces rising competition, so sustainability depends on upcoming regulatory wins (Tyvaso IPF, ralinepag and device filings) and execution on launches; absent those catalysts the international uptick could prove transient.

Data provided by:The Fly

United Therapeutics (UTHR) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%25%30%UTHR+23.84%SPY+12.87%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$25.04B
Dividend Yield
―
Average Volume (3M)
694.95K
Price to Earnings (P/E)
20.5
Beta (1Y)
0.50
Revenue Growth
1.89%
EPS Growth
0.33%
Country
US
Employees
1,400
Sector
Healthcare
Sector Strength
51
Industry
Biotechnology

United Therapeutics Business Overview & Revenue Model

Company Description

United Therapeutics Corporation, a biotechnology firm, is dedicated to discovering, developing, and bringing to market medical solutions for individuals suffering from chronic and severe, often life-threatening, illnesses. Its operations span both th...

How the Company Makes Money

United Therapeutics makes money primarily by selling branded prescription medicines, with its core revenue derived from PAH therapies. Key revenue streams include: (1) Product sales of PAH medicines in the U.S. and internationally, sold through speci...

United Therapeutics Earnings Call Summary

Earnings Call Date:Nov 04, 2026(Q3-2026)|% Change Since:-2.24%|Next Earnings Date:Feb 24, 2027
Earnings Call SentimentPositive

The call was strongly positive, led by record total and Tyvaso revenue, improving referral and demand trends, favorable intellectual property and settlement developments, and confidence in a broad pipeline and upcoming launches. The main negatives were execution and regulatory timing issues, including the delayed soft mist inhaler filing, the ralinepag API supplier’s OAI status, uncertainty around the triple oral pill filing path, and moderate near-term patient switching expectations.

Positive Updates

Record Third-Quarter Revenue
United Therapeutics delivered record total revenue of $833 million in the third quarter of 2026, which management described as the company’s best quarter ever.

Negative Updates

Soft Mist Inhaler NDA Filing Delayed
After meeting with the FDA, United Therapeutics determined that additional data is needed to support the soft mist inhaler application. The company now expects to submit the NDA in 2027 rather than at the end of 2026.

Company Guidance

Management expects near-term transitions from YUTREPIA to Tyvaso to be moderate, with a PH-ILD referral inflection expected over the next couple weeks, and into December, and then obviously the first part of the year, followed by a new baseline in referrals over the next few weeks; it expects to submit the soft mist inhaler NDA in 2027 and not at the end of this year, while oral ralinepag has a PDUFA date of June 24 of next year. Management also expects nebulized Tyvaso in IPF and ralinepag in PAH to become multi-billion dollar growth drivers, expects to enter 2027 with substantially more momentum than entering 2026, and reported $833 million of third-quarter total revenue, $504 million of Tyvaso revenue, over 1,000 referrals in October, and that one in three patients starting TYVASO DPI since the introduction of higher-strength cartridges achieved higher doses, twice as what it was beforehand.

United Therapeutics Financial Statement Overview

Summary

Financials are high-quality: very strong profitability (TTM gross margin ~86%, EBIT margin ~50%, net margin ~42%) and an exceptionally conservative balance sheet with effectively no debt (Total Debt: $0 TTM). Cash generation remains strong (TTM operating cash flow ~$1.43B), but the score is tempered by decelerating growth (TTM revenue ~1%) and a meaningful decline in TTM free cash flow (down ~21% to ~$867M).

Income Statement

92Very Positive

Balance Sheet

95Very Positive

Cash Flow

80Positive
Financial statement breakdown
BreakdownTTMDec 2025Dec 2024Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue3.19B3.18B2.88B2.33B1.94B1.69B
Gross Profit2.75B2.80B2.57B2.07B1.79B1.56B
EBITDA1.58B1.82B1.65B1.39B1.04B736.80M
Net Income1.23B1.33B1.20B984.80M727.30M475.80M
Balance Sheet
Total Assets7.03B7.88B7.36B7.17B6.04B5.17B
Cash, Cash Equivalents and Short-Term Investments2.07B1.56B3.27B2.99B2.84B1.93B
Total Debt037.60M300.00M700.00M800.00M800.00M
Total Liabilities758.10M783.80M920.00M1.18B1.25B1.21B
Stockholders Equity6.28B7.10B6.44B5.98B4.80B3.96B
Cash Flow
Free Cash Flow867.20M1.04B1.08B747.60M663.70M477.40M
Operating Cash Flow1.43B1.56B1.33B978.00M802.50M598.20M
Investing Cash Flow93.00M-551.30M417.20M-719.60M-811.50M-486.90M
Financing Cash Flow-1.67B-1.15B-1.25B-11.90M75.40M44.80M

United Therapeutics Technical Analysis

Technical Analysis SentimentPositive
Last Price587.88

Price Trends

50DMA544.61Positive
100DMA535.15Positive
200DMA538.05Positive

Market Momentum

MACD11.88Positive
RSI56.40Neutral
STOCH59.30Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For UTHR, the sentiment is Positive. The current price of 587.88 is above the 20-day moving average (MA) of 586.26, above the 50-day MA of 544.61, and above the 200-day MA of 538.05, indicating a bullish trend. The MACD of 11.88 indicates Positive momentum. The RSI at 56.40 is Neutral, neither overbought nor oversold. The STOCH value of 59.30 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for UTHR.

United Therapeutics Risk Analysis

United Therapeutics disclosed 32 risk factors in its most recent earnings report. United Therapeutics reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.Management's Discussion and Analysis of Financial Condition and Results of Operations-Generic Competition and Challenges to our Intellectual Property Rights.Q1, 2025
2.If we are not able to successfully identify, finance, consummate and/or integrate acquisitions, our business operations and financial position could be adversely affected.Q4, 2023
3.Cybersecurity incidents and other disruptions impacting our networks, systems, or data may have a material adverse effect on our business.Q4, 2023

United Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

UTHR against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
UTHRUTHR85Outperform$25.04B20.5419.18%―1.89%0.33%
ALNYALNY70Outperform$21.39B7.82159.72%―56.17%6459.20%
JAZZJAZZ66Neutral$15.39B67.294.62%―13.48%―
INSMINSM65Neutral$26.96B-43.68-82.75%―239.97%54.44%
BMRNBMRN56Neutral$11.23B-645.55-0.31%―19.76%-103.57%
BBIOBBIO53Neutral$15.07B-25.4426.76%―167.27%27.40%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%

* Healthcare Sector Average

Performance Comparison

-50%-25%0%25%UTHRALNYBMRNINSMJAZZBBIODec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
UTHR and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
UTHRUnited Therapeutics Corp.587.88111.3423.36%
ALNYAlnylam Pharmaceuticals159.73-301.03-65.33%
BMRNBiomarin Pharmaceutical Inc.57.995.4310.33%
INSMInsmed122.88-80.68-39.63%
JAZZJazz Pharmaceuticals239.7763.6936.17%
BBIOBridgebio Pharma77.3611.8218.03%

United Therapeutics Corporate Events

Business Operations and StrategyStock Buyback

United Therapeutics Announces $2 Billion Share Buyback

Positive
Oct 22, 2026

On October 21, 2026, United Therapeutics Corporation’s board approved a new share repurchase program authorizing the buyback of up to $2 billion of its common stock over a one-year period ending October 21, 2027. The move, announced publicly on Octob...

Business Operations and StrategyLegal Proceedings

United Therapeutics Reaches Major Pulmonary Hypertension Settlement

Positive
Oct 14, 2026

On October 13, 2026, United Therapeutics entered a settlement agreement with Liquidia Technologies that will resolve multiple patent and trade secret disputes over inhaled treprostinil products, including UT’s Tyvaso DPI and Liquidia’s Yutrepia. Liqu...

Business Operations and StrategyStock Buyback

United Therapeutics Announces New Accelerated Share Repurchase

Positive
Sep 8, 2026

On September 8, 2026, United Therapeutics entered into an accelerated share repurchase agreement with Citibank to buy back approximately $477.6 million of its common stock, using the remaining portion of its previously authorized $2 billion share rep...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 04, 2026